These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 4037732)
1. Mitogen stimulation of blood lymphocytes from patients with primary intracranial tumors. Correlation to histological tumor type. Blom U; Blomgren H; Ullén H; Collins P; Von Holst H Anticancer Res; 1985; 5(4):343-8. PubMed ID: 4037732 [TBL] [Abstract][Full Text] [Related]
2. Capacity of sera from patients with primary intracranial tumors to support mitogen stimulation of blood lymphocytes. Correlation to histological tumor type. Blomgren H; Blom U; Ullén H Anticancer Res; 1985; 5(4):349-54. PubMed ID: 4037733 [TBL] [Abstract][Full Text] [Related]
3. [Immunological monitoring of brain tumors--prognosis based on T-lymphocyte subpopulations and skin testing for delayed hypersensitivity]. Yokoyama H; Nakadai M; Asou Y; Maeda T; Ogashiwa M; Takeuchi K No To Shinkei; 1985 Feb; 37(2):193-9. PubMed ID: 3873952 [TBL] [Abstract][Full Text] [Related]
4. Microvessel density in brain tumors. Assimakopoulou M; Sotiropoulou-Bonikou G; Maraziotis T; Papadakis N; Varakis I Anticancer Res; 1997; 17(6D):4747-53. PubMed ID: 9494601 [TBL] [Abstract][Full Text] [Related]
5. Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. Elliott LH; Brooks WH; Roszman TL J Immunol; 1984 Mar; 132(3):1208-15. PubMed ID: 6319491 [TBL] [Abstract][Full Text] [Related]
6. [Immunological monitoring of brain tumors--prognosis and cellular immunity of patients with brain tumors]. Yokoyama H; Hara M; Ogashiwa M; Takeuchi K No To Shinkei; 1983 Nov; 35(11):1103-8. PubMed ID: 6661336 [TBL] [Abstract][Full Text] [Related]
7. Blood lymphocyte subsets in patients with primary intracranial tumours. Correlation to histological tumour type and anatomical site. Ullén H; Blom U; Blomgren H; von Holst H Acta Neurochir (Wien); 1986; 81(3-4):100-5. PubMed ID: 3489354 [TBL] [Abstract][Full Text] [Related]
8. [Analysis of tumor specific immunological response in the patients with malignant brain tumors by the mixed lymphocyte-tumor cell reaction]. Yoshida S; Takai N; Ono K; Saito T; Tanaka R No To Shinkei; 1988 Nov; 40(11):1067-73. PubMed ID: 2975495 [TBL] [Abstract][Full Text] [Related]
9. [Histological and molecular classification of gliomas]. Figarella-Branger D; Colin C; Coulibaly B; Quilichini B; Maues De Paula A; Fernandez C; Bouvier C Rev Neurol (Paris); 2008; 164(6-7):505-15. PubMed ID: 18565348 [TBL] [Abstract][Full Text] [Related]
10. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179 [TBL] [Abstract][Full Text] [Related]
11. Relation between the site of primary intracranial tumors and mitogenic responses of blood lymphocytes. Blomgren H; Blom U; Ulén H Cancer Immunol Immunother; 1986; 21(1):31-8. PubMed ID: 3632915 [TBL] [Abstract][Full Text] [Related]
12. Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. Roszman TL; Brooks WH Clin Exp Immunol; 1980 Feb; 39(2):395-402. PubMed ID: 6966992 [TBL] [Abstract][Full Text] [Related]
13. Neuropathology of malignant gliomas. Bruner JM Semin Oncol; 1994 Apr; 21(2):126-38. PubMed ID: 8153659 [TBL] [Abstract][Full Text] [Related]
14. Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2). Yamamoto M; Fukushima T; Hayashi S; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M Anticancer Res; 2000; 20(1C):611-8. PubMed ID: 10769704 [TBL] [Abstract][Full Text] [Related]
15. Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema. Server A; Kulle B; Maehlen J; Josefsen R; Schellhorn T; Kumar T; Langberg CW; Nakstad PH Acta Radiol; 2009 Jul; 50(6):682-9. PubMed ID: 19449234 [TBL] [Abstract][Full Text] [Related]
16. Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Hughes MA; Parisi M; Grossman S; Kleinberg L Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1423-6. PubMed ID: 16029802 [TBL] [Abstract][Full Text] [Related]
17. Natural killer activity of blood lymphocytes in patients with primary intracranial tumors. Correlation to histological tumor type and anatomical site. Ullén H; Blom U; Blomgren H Eur J Cancer Clin Oncol; 1986 Oct; 22(10):1239-45. PubMed ID: 3816915 [TBL] [Abstract][Full Text] [Related]
18. T cell adoptive immunotherapy of newly diagnosed gliomas. Plautz GE; Miller DW; Barnett GH; Stevens GH; Maffett S; Kim J; Cohen PA; Shu S Clin Cancer Res; 2000 Jun; 6(6):2209-18. PubMed ID: 10873070 [TBL] [Abstract][Full Text] [Related]
19. Immunoregulatory cell function in peripheral blood leukocytes of patients with intracranial gliomas. Braun DP; Penn RD; Flannery AM; Harris JE Neurosurgery; 1982 Feb; 10(2):203-9. PubMed ID: 6280097 [TBL] [Abstract][Full Text] [Related]
20. In vitro analysis of the proliferative potential of T cells from patients with brain tumor: glioma-associated immunosuppression unrelated to intrinsic cellular defect. McVicar DW; Davis DF; Merchant RE J Neurosurg; 1992 Feb; 76(2):251-60. PubMed ID: 1730954 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]